HOME >> MEDICINE >> NEWS
Wistar Institute Facility distinguished as center of excellence by Ben Franklin Technology PArtners of Southeastern Pennsylvania for second year

r; David Speicher, Ph.D., is consultant. Both Wistar professors, the two established the Center by combining Wistar's Expression Vector-Recombinant Protein Production Facility and its Protein Microchemistry/Mass Spectrometry Facility.

According to Dr. Wunner, "the combination of multi-disciplined and centralized services Wistar provides gives companies a unique opportunity to obtain a novel recombinant protein and a complete product assessment with regard to protein structure." As an additional benefit, Ben Franklin will grant new Pennsylvania companies up to $5,000 toward services rendered by the Institute.

The Ben Franklin Technology PArtners of Southeastern Pennsylvania is a statewide network that promotes economic development and competitiveness in southeastern Pennsylvania through technology and innovation. As part of the statewide Ben Franklin Partnership, Ben Franklin supports the development of technology-based enterprises through a portfolio of investment and client-oriented service programs.


'"/>

Contact: Diana Cutshall
dcutshall@wistar.upenn.edu
215-898-3716
The Wistar Institute
22-Jul-1999


Page: 1 2

Related medicine news :

1. Director of AIDS Research Center to give Wistar Institutes 1999 Jonathan Lax Memorial Lecture
2. Wistar scientist receives Arthritis Foundation award
3. National Cancer Institute awards Wistar Institute $6.6 million for melanoma research
4. Wistar scientist awarded American Cancer Society grant for research on tumor killing cells
5. Research Grant To Wistar Institute Involves Linda Creed Breast Cancer Foundation In Breast Cancer Research
6. Lupus Foundation Of America Awards Summer Internship To Student Working At Wistar Institute
7. Wistar Scientist Awarded American Cancer Society Grant For Study Of Tumor Suppressor Proteins
8. Gladstone Institutes rank high in the scientist survey of best places for postdocs
9. Institute of Medicine advisory: Jan. 12 Briefing on Complementary and Alternative Medicine
10. Research by scientists affiliated with the Earth Institute at Columbia University
11. New Jersey Institute of Technology pioneers new way to teach engineers

Post Your Comments:
(Date:10/22/2014)... (PRWEB) October 22, 2014 On Saturday, October ... its fourth annual family health and fitness fair ¡Vive tu ... physical activity and good nutrition for better health and wellness ... which is free and open to the public, will be ... Brownsville, from 9:00 am to 1:00 pm. , “¡Vive ...
(Date:10/22/2014)... (PRWEB) October 22, 2014 For Dr. Iris ... make money; it’s an extension of her life’s mission. Her ... venture as the owner of FirstLight HomeCare, make it clear ... important to me that my work makes a difference in ... an entrepreneurial spirit, so after much research, I felt ready ...
(Date:10/22/2014)... The Louis W. Sullivan Institute ... distribute health information technology innovation to transform quality ... development of six key guiding principles of patient-centered ... These are an expansion of the Institute of ... is respectful of and responsive to individual patient ...
(Date:10/22/2014)... Best Cheap Hosting USA is among ... site has recently announced that iPower ( http://www.best-cheap-hosting-usa.com/go/iPower/ ) ... from around the world. , “iPower is one of ... is providing various kinds of useful products for new ... offering excellent customer service and a number of features ...
(Date:10/22/2014)... (PRWEB) October 22, 2014 Lintelus, Inc., ... Sr. Vice President of Sales, will be speaking on ... Meetings Technology Expo on October 28, at the Holiday ... hosting a booth as well as a Tech Demo ... Meeting can create a more engaging event experience. , ...
Breaking Medicine News(10 mins):Health News:Brownsville Community Health Center Presents Fourth Annual ¡Vive Tu Vida! Get Up! Get Moving!® Event 2Health News:Brownsville Community Health Center Presents Fourth Annual ¡Vive Tu Vida! Get Up! Get Moving!® Event 3Health News:Brownsville Community Health Center Presents Fourth Annual ¡Vive Tu Vida! Get Up! Get Moving!® Event 4Health News:Dr. Iris Hunter to Host Grand Opening of FirstLight HomeCare Tomorrow 2Health News:The Sullivan Institute for Healthcare Innovation Announces Release of Guiding Principles for Patient Experience-Centered Care 2Health News:Best Cheap Hosting USA Has Recently Announced The Best Cheap Web Hosting Companies In 2014 2Health News:Jay Cormier, Sr. Vice President of Sales for Lintelus, Speaks about Event Technology Integration at Meetings Technology Expo in NYC 2
(Date:10/22/2014)... 22, 2014 Sanomedics International Holdings, Inc. (OTCQB: ... Global Research & Data Services, demand for thermometers is ... through 2018, as demand for more accurate digital thermometers ... the world,s largest market for thermometers, and one of ... Sanomedics International Holdings, Inc. Sanomedics International Holdings ...
(Date:10/22/2014)... NEW YORK , Oct. 22, 2014 ... and dermatology therapies. PV-10, its novel investigational drug for ... the potential for systemic side effects. Its oncology focus ... liver. Provectus has completed phase 2 trials of PV-10 ... as a topical treatment for atopic dermatitis and psoriasis. ...
(Date:10/22/2014)... LA JOLLA, Calif. , Oct. 22, ... RGLS ), a biopharmaceutical company leading ... targeting microRNAs, today announced that it has ... from an ongoing clinical study evaluating RG-101, ... for the treatment of hepatitis C virus ...
Breaking Medicine Technology:Sanomedics International Holdings Analyst Report: Taking Some Heat by BrokerBank Securities, Inc. 2Provectus Biopharmaceuticals Looks at the Asian Markets: Analyst Coverage by Small Cap Traders 2A Single Subcutaneous Dose of 2mg/kg of RG-101, Regulus' Wholly-Owned, GalNac-Conjugated anti-miR Targeting microRNA-122, Demonstrates 4.1 log10 Mean Viral Load Reduction as Monotherapy at Day 29 in Patients with Varied HCV Genotypes and Treatment H 2A Single Subcutaneous Dose of 2mg/kg of RG-101, Regulus' Wholly-Owned, GalNac-Conjugated anti-miR Targeting microRNA-122, Demonstrates 4.1 log10 Mean Viral Load Reduction as Monotherapy at Day 29 in Patients with Varied HCV Genotypes and Treatment H 3A Single Subcutaneous Dose of 2mg/kg of RG-101, Regulus' Wholly-Owned, GalNac-Conjugated anti-miR Targeting microRNA-122, Demonstrates 4.1 log10 Mean Viral Load Reduction as Monotherapy at Day 29 in Patients with Varied HCV Genotypes and Treatment H 4A Single Subcutaneous Dose of 2mg/kg of RG-101, Regulus' Wholly-Owned, GalNac-Conjugated anti-miR Targeting microRNA-122, Demonstrates 4.1 log10 Mean Viral Load Reduction as Monotherapy at Day 29 in Patients with Varied HCV Genotypes and Treatment H 5A Single Subcutaneous Dose of 2mg/kg of RG-101, Regulus' Wholly-Owned, GalNac-Conjugated anti-miR Targeting microRNA-122, Demonstrates 4.1 log10 Mean Viral Load Reduction as Monotherapy at Day 29 in Patients with Varied HCV Genotypes and Treatment H 6A Single Subcutaneous Dose of 2mg/kg of RG-101, Regulus' Wholly-Owned, GalNac-Conjugated anti-miR Targeting microRNA-122, Demonstrates 4.1 log10 Mean Viral Load Reduction as Monotherapy at Day 29 in Patients with Varied HCV Genotypes and Treatment H 7A Single Subcutaneous Dose of 2mg/kg of RG-101, Regulus' Wholly-Owned, GalNac-Conjugated anti-miR Targeting microRNA-122, Demonstrates 4.1 log10 Mean Viral Load Reduction as Monotherapy at Day 29 in Patients with Varied HCV Genotypes and Treatment H 8
Cached News: